Fisiopatología de la hepatitis C y diabetes mellitus. Hacia la cura de dos epidemias en el siglo XXI

  • Harold Ariel Muñoz Díaz Hospital Universitario Nacional
  • Adán José Lúquez Mindiola Universidad Nacional de Colombia http://orcid.org/0000-0001-5364-9688
  • Andrés José Gómez Aldana Fundación Santa Fé y Centro de enfermedades digestiva GutMédica, Bogotá
Palabras clave: hepatitis C, hepatitis C crónica, diabetes mellitus

Resumen

La infección crónica por virus de la hepatitis C (VHC) y la diabetes mellitus (DM) son dos problemas de salud pública que impactan los sistemas de salud, con una alta carga económica global. La infección por VHC produce manifestaciones hepáticas tales como hepatitis, cirrosis y carcinoma hepatocelular; asimismo, se ha involucrado en la patogénesis de manifestaciones extrahepáticas, entre las cuales se ha asociado con alteraciones metabólicas como la DM. Estudios longitudinales y transversales han reportado mayor incidencia y prevalencia de DM en pacientes con infección crónica por VHC. La DM acelera la progresión histológica y clínica en pacientes con infección crónica por VHC y las complicaciones cardiovasculares. Recientemente se ha avanzado en el tratamiento y la introducción de nuevos medicamentos como los antivirales de acción directa, que mejoran el control glucémico en estos pacientes.

Biografía del autor/a

Harold Ariel Muñoz Díaz, Hospital Universitario Nacional
Especialista en medicina interna
Adán José Lúquez Mindiola, Universidad Nacional de Colombia
Especialista en gastroenterología. Gastroenterólogo en Centro de enfermedades digestivas GutMédica, Bogotá
Andrés José Gómez Aldana, Fundación Santa Fé y Centro de enfermedades digestiva GutMédica, Bogotá
Especialista en gastroenterología

Citas

Stepanova M, Younossi ZM. Economic burden of hepatitis C. Clin Liver Dis. 2017;21:579-94. doi: 10.1016/j.cld.2017.03.012.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14. doi: 10.1016/j.diabres.2009.10.007.

Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2015;38:1777-803. doi: 10.2337/dci15-0012.

Vaidya V, Gangan N, Sheehan J. Impact of cardiovascular complications among patients with type 2 diabetes mellitus: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015;15:487-97. doi: 10.1586/14737167.2015.1024661.

Barbeau WE. What is the key environmental trigger in type 1 diabetes--is it viruses, or wheat gluten, or both? Autoimmun Rev. 2012;12:295-9. doi: 10.1016/j.autrev.2012.05.003.

Askenasy EM, Askenasy N. Is autoimmune diabetes caused by aberrant immune activity or defective suppression of physiological self-reactivity? Autoimmun Rev 2013;12:633-7. doi: 10.1016/j.autrev.2012.12.004.

Ferrannini E. Physiology of glucose homeostasis and insulin therapy in type 1 and type 2 diabetes. Endocrinol Metab Clin North Am. 2012;41:25-39. doi: 10.1016/j.ecl.2012.01.003.

Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122-32. doi: 10.1038/nrgastro.2016.176.

Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol. 2015;7:2676-80. doi: 10.4254/wjh.v7.i26.2676.

Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436-41. doi: 10.3748/wjg.v13.i17.2436.

Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-42. doi: 10.1002/hep.26141.

Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol. 2008;26(1 Suppl 48): S39-47.

Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis. 2007;39(Suppl 1):S13-21. doi: 10.1016/S1590-8658(07)80005-3.

Nocente R, Ceccanti M, Bertazzoni G, Cammarota G, Silveri NG, Gasbarrini G. HCV infection and extrahepatic manifestations. Hepatogastroenterology. 2003;50:1149-54.

Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328-33. doi: 10.1002/hep.510290235.

Weinman SA, Belalcazar LM. Hepatitis C: a metabolic liver disease. Gastroenterology 2004; 126: 917-9. doi: 10.1053/j.gastro.2003.01.001.

Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987-1000. doi: 10.1002/hep.20920.

Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51(6):1889-95. doi: 10.2337/diabetes.51.6.1889.

Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol. 2006;12:7075-80. doi: 10.3748/wjg.v12.i44.7075.

Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35:279-83. doi: 10.1016/S0168-8278(01)00143-X.

Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003;38:50-6. doi: 10.1053/jhep.2003.50291.

Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102:1237-43. doi: 10.1111/j.1572-0241.2007.01181.x.

Boluda Monzo S, Mesa Manteca J, Obiols Alfonso G, Simo Canonge R. Surface antigen of hepatitis B in diabetes mellitus. Med Clin (Barc). 1989;92:397.

Mangia A, Schiavone G, Lezzi G, Marmo R, Bruno F, Villani MR, et al. HCV and diabetes mellitus: evidence for a negative association. Am J Gastroenterol. 1998;93:2363-7. doi: 10.1111/j.1572-0241.1998.00688.x.

Ozyilkan E, Erbas T, Simsek H, Telatar F, Kayhan B, Telatar H. Increased prevalence of hepatitis C virus antibodies in patients with diabetes mellitus. J Intern Med. 1994;235:283-4. doi: 10.1111/j.1365-2796.1994.tb01075.x.

Gray H, Wreghitt T, Stratton IM, Alexander GJ, Turner RC, O'Rahilly S. High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med. 1995;12:244-9. doi: 10.1111/j.1464-5491.1995.tb00466.x.

Fabiani S, Fallahi P, Ferrari SM, Miccoli M, Antonelli A. Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature. Rev Endocr Metab Disord. 2018;19(4):405-20. doi: 10.1007/s11154-017-9440-1.

Sotiropoulos A, Peppas TA, Skliros E, Apostolou O, Kotsini V, Pappa SI. Low prevalence of hepatitis C virus infection in Greek diabetic patients. Diabet Med. 1999;16:250-2. doi: 10.1046/j.1464-5491.1999.00009.x.

Ryu JK, Lee SB, Hong SJ, Lee S. Association of chronic hepatitis C virus infection and diabetes mellitus in Korean patients. Korean J Intern Med. 2001;16:18-23. doi: 10.3904/kjim.2001.16.1.18.

Okan V, Araz M, Aktaran S, Karsligil T, Meram I, Bayraktaroglu Z, et al. Increased frequency of HCV but not HBV infection in type 2 diabetic patients in Turkey. Int J Clin Pract. 2002;56:175-7.

Cerutti F, Palomba E, Sacchetti C, Gay V, Versace A, Tovo PA. Anti-HCV antibodies in a population of insulin-dependent diabetic children and adolescents. Diabetes Care. 1999;22:1587-8. doi: 10.2337/diacare.22.9.1587.

Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592-9. doi: 10.7326/0003-4819-133-8-200010170-00009.

Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Community-based study of hepatitis C virus infection and type 2 diabetes: an association affected by age and hepatitis severity status. Am J Epidemiol. 2003;158:1154-60. doi: 10.1093/aje/kwg259.

Garrido Serrano A, Guerrero Igea FJ, Lepe Jimenez JA, Palomo Gil S, Grilo Reina A. Hyperinsulinemia in cirrhotic patients infected with hepatitis C virus infection. Gastroenterol Hepatol. 2001;24:127-31. doi: 10.1016/S0210-5705(01)70138-0.

Simo R, Hernandez C, Genesca J, Jardi R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996;19:998-1000. doi: 10.2337/diacare.19.9.998.

Grimbert S, Valensi P, Levy-Marchal C, Perret G, Richardet JP, Raffoux C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C: a case-control study. Gastroenterol Clin Biol. 1996;20:544-8.

Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc. 2000;75:355-9. doi: 10.4065/75.4.355.

Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race: a case-control study. Am J Gastroenterol. 2003;98:438-41.

Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr. 2003;33:577-84. doi: 10.1097/00126334-200308150-00005.

Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology. 2003;125:1695-704. doi: 10.1053/j.gastro.2003.08.032.

Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001;59:732-7. doi: 10.1046/j.1523-1755.2001.059002732.x.

Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001;72:1066-72. doi: 10.1097/00007890-200109270-00015.

Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Koff JM, Holtzmuller KC, et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol. 2004;15:3166-74. doi: 10.1097/01.ASN.0000145439.48387.BF.

Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care. 2004;27:1171-5. doi: 10.2337/diacare.27.5.1171.

American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13-S28. doi: 10.2337/dc19-S002.

Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care. 2005;28:940-1. doi: 10.2337/diacare.28.4.940.

Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840-8. doi: 10.1053/j.gastro.2003.11.056.

Bureau C, Bernad J, Chaouche N, Orfila C, Béraud M, Gonindard C, et al. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem. 2001;276:23077-83. doi: 10.1074/jbc.M100698200.

Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol. 2008;82:2606-12. doi: 10.1128/JVI.01672-07.

Burén J, Liu HX, Jensen J, Eriksson JW. Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. Eur J Endocrinol. 2002;146:419-29. doi: 10.1530/eje.0.1460419.

Negro F. Mechanisms of hepatitis C virus-related insulin resistance. Clin Res Hepatol Gastroenterol. 2011;35:358-63. doi: 10.1016/j.clinre.2011.01.011.

Gastaldi G, Goossens N, Clément S, Negro F. Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. J Adv Res. 2017;8:149-59. doi: 10.1016/j.jare.2016.11.003.

Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med. 2013;19:879-88. doi: 10.1038/nm.3253.

Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab. 2002;87:2084-9. doi: 10.1210/jcem.87.5.8450.

Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci. 1997;42:2487-94. doi: 10.1023/A:1018804426724.

Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001;19:378-87. doi: 10.1634/stemcells.19-5-378.

Oncül O, Top C, Cavuplu T. Correlation of serum leptin levels with insulin sensitivity in patients with chronic hepatitis-C infection. Diabetes Care 2002; 25: 937. doi: 10.2337/diacare.25.5.937.

Mankouri J, Tedbury PR, Gretton S, Hughes ME, Griffin SD, Dallas ML, et al. Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc Natl Acad Sci USA. 2010;107:11549-11554. doi: 10.1073/pnas.0912426107.

Cheung AT, Wang J, Ree D, Kolls JK, Bryer-Ash M. Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes 2000; 49: 810-9. doi: 10.2337/diabetes.49.5.810.

Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev. 2003;14:447-55. doi: 10.1016/S1359-6101(03)00052-2.

Fallahi P, Ferri C, Ferrari SM, Corrado A, Sansonno D, Antonelli A. Cytokines and HCV-related disorders. Clin Dev Immunol. 2012;2012:468107. doi: 10.1155/2012/468107.

Antonelli A, Ferri C, Fallahi P, Ferrari SM, Sebastiani M, Ferrari D, et al. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol. 2008;103:2488-94. doi: 10.1111/j.1572-0241.2008.02040.x.

Eslam M, Booth DR, George J, Ahlenstiel G. Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World J Gastroenterol. 2013;19:7055-61. doi: 10.3748/wjg.v19.i41.7055.

Yan FM, Chen AS, Hao F, Zhao XP, Gu CH, Zhao LB, et al. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J Gastroenterol. 2000;6:805-11. doi: 10.3748/wjg.v6.i6.805.

Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab. 2009;5:26-34. doi: 10.1038/ncpendmet1027.

Bogdanos DP, Rigopoulou EI. Viral/self-mimicry and immunological cross-reactivity as a trigger of hepatic C virus associated autoimmune diabetes. Diabetes Res Clin Pract. 2007;77:155-6. doi: 10.1016/j.diabres.2006.10.012.

Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001;12:53-72. doi: 10.1016/S1359-6101(00)00015-0.

Yumoto E, Higashi T, Nouso K, Nakatsukasa H, Fujiwara K, Hanafusa T, et al. Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J Gastroenterol Hepatol. 2002;17:285-94. doi: 10.1046/j.1440-1746.2002.02690.x.

Lee LF, Xu B, Michie SA, Beilhack GF, Warganich T, Turley S, et al. The role of TNF-alpha in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: analysis of dendritic cell maturation. Proc Natl Acad Sci USA. 2005;102:15995-6000. doi: 10.1073/pnas.0508122102.

Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Garcia L, et al. Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection. Diabetes Care. 2004;27:2669-75. doi: 10.2337/diacare.27.11.2669.

Ramalho F. Hepatitis C virus infection and liver steatosis. Antiviral Res. 2003;60:125-7. doi: 10.1016/j.antiviral.2003.08.007.

Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Petraki K, et al. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol. 2007;102:634-41. doi: 10.1111/j.1572-0241.2006.01025.x.

Schreuder TC, Gelderblom HC, Weegink CJ, Hamann D, Reesink HW, Devries JH, et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int. 2008;28:39-46. doi: 10.1111/j.1478-3231.2007.01610.x.

Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, et al. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care. 2000;23:1177-181. doi: 10.2337/diacare.23.8.1177.

Chakrabarti D, Hultgren B, Stewart TA. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol. 1996;157:522-8.

Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-41. doi: 10.1053/j.gastro.2004.12.049.

Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug induced apoptosis. Biochem Pharmacol. 2004;68:1003-15. doi: 10.1016/j.bcp.2004.05.029.

Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, Hsieh CC, et al. Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer. 2000;87:118-21. doi: 10.1002/1097-0215(20000701)87:1<118::aid-ijc17>3.0.co;2-w.

Dyal KH, Aguilar M, Bartos G, Holt WE, Bhuket T, Liu B, et al. Diabetes Mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review. Dig Dis Sci. 2016;61:636-45. doi: 10.1007/s10620-015-3983-3.

Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57:964-73. doi: 10.1002/hep.26087.

Ikeda A, Ikeda K, Takai A, Takahashi K, Ueda Y, Marusawa H, et al. Hepatitis C treatment with sofosbuvir and ledipasvir accompanied by immediate improvement in hemoglobin A1C. Digestion. 2017;96:228-30. doi: 10.1159/000484237.

Adinolfi LE, Nevola R, Guerrera B, D'Alterio G, Marrone A, Giordano M, et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33:1379-82. doi: 10.1111/jgh.14067.

Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E, et al. Significant improvement of glycemic control in diabetes patients with HCV infection responding to direct-acting antiviral agents. J Med Virol. 2018;90:320-7. doi: 10.1002/jmv.24954.

Dawood AA, Nooh MZ, Elgamal AA. Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4. Diabetes Metab J. 2017;41:316-21. doi: 10.4093/dmj.2017.41.4.316.

Abdel-Hamid N, Jubori TA, Farhan A, Mahrous M, Gouri A, Awad E, et al. Underlying pathways for interferon risk to type II diabetes mellitus. Curr Diabetes Rev. 2013;9(6):472-7.

Li J, Zhang T, Gordon SC, Rupp LB, Trudeau S, Holmberg SD, et al. Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United States. J Viral Hepat. 2018;25(8):952-958. doi: 10.1111/jvh.12887.

Li J, Gordon SC, Rupp LB, Zhang T, Trudeau S, Holmberg SD, et al. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Aliment Pharmacol Ther. 2019;49:599-608. doi: 10.1111/apt.15102.

Gilad A, Fricker ZP, Hsieh A, Thomas DD, Zahorian T, Nunes DP. Sustained Improvement in Type 2 Diabetes Mellitus is Common After Treatment of Hepatitis C Virus With Direct-acting Antiviral Therapy. J Clin Gastroenterol. 2019;53(8):616-20. doi: 10.1097/MCG.0000000000001168.

Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, et al. Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus. Diabetes Care. 2017;40:1173-80. doi: 10.2337/dc17-0485.

Crook ED, Penumalee S, Gavini B, Filippova K. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care 2005;28:2187-91. doi: 10.2337/diacare.28.9.2187.

Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2006;55:529-35. doi: 10.1136/gut.2005.069674.

Sanyal AJ. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int. 2011;31(Suppl 1):23-8. doi: 10.1111/j.1478-3231.2010.02397.x.

Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642-6. doi: 10.1126/science.1120781.

O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology. 2007;45:895-8. doi: 10.1002/hep.21554.

Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev. 2009;18:2054-60. doi: 10.1158/1055-9965.EPI-08-1131.

Publicado
2019-10-07
Cómo citar
Muñoz Díaz, H. A., Lúquez Mindiola, A. J., & Gómez Aldana, A. J. (2019). Fisiopatología de la hepatitis C y diabetes mellitus. Hacia la cura de dos epidemias en el siglo XXI. Revista Colombiana De Gastroenterología, 34(3), 277-287. https://doi.org/10.22516/25007440.322
Sección
Revisión de tema